zileuton has been researched along with naproxen in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (43.48) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kreft, AF; Musser, JH | 1 |
| Calhoun, W; Carlson, RP; Crossley, R; Datko, LJ; Dietrich, S; Heatherington, K; Marshall, LA; Meade, PJ; Opalko, A; Shepherd, RG | 1 |
| Adams, JL; Badger, AM; Boehm, JC; Bradbeer, J; Breton, JJ; Chabot-Fletcher, MC; Gallagher, TF; Garigipati, RS; Griswold, DE; Hillegass, LM; Laydon, JT; Lee, JC; Sheldrake, PL; Smietana, JM; Sorenson, ME | 1 |
| Bell, RL; Bouska, J; Brooks, CD; Carter, GW; Dellaria, JF; Hulkower, KI; Kolasa, T; Rodriques, KE; Summers, JB | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, WM; Albert, L; Behnke, ML; Chen, L; Clark, JD; Donahue, F; Foley, MA; Goodwin, DG; Hegen, M; Hu, B; Hu, Y; Ipek, M; Keith, J; Kirincich, SJ; Ku, MS; Lee, KL; McKew, JC; Michalak, R; Murphy, EA; Nickerson-Nutter, CL; Ramarao, MK; Shen, MW; Sum, FW; Tam, S; Thakker, P; Thomason, J; Williams, C; Wooder, L; Wu, K; Xu, X | 1 |
| Chen, L; Clark, JD; Goodwin, DG; Lee, KL; McKew, JC; Murphy, EA; Nickerson-Nutter, C; Shen, MW; Tam, S; Wang, W; Xu, X; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kazmi, SM; Lau, CY; Plante, RK; Taylor, GR; Visconti, V; Zhou, L | 1 |
| Colombo, C; DiPasquale, G; Fryer, LR; Greenspan, PD; Haston, W; Healy, C; Kotyuk, B; Pastor, G; Pellas, TC; Raychaudhuri, A | 1 |
| Chourmouzis, E; Fung-Leung, WP; Lau, CY; Pope, BL; Zhou, L | 1 |
| Medvedeff, ED; Nickerson-Nutter, CL | 1 |
| Awni, WM; Braeckman, RA; Cavanaugh, JH; Dubé, LM; Granneman, GR; Linnen, PJ; Locke, CS | 1 |
| Bopp, BA; Kukulka, MJ; Machinist, JM | 1 |
| Borey, AJ; Clark, JD; Cui, J; Donahue, F; Han, L; Hassan-Zahraee, M; Leach, MW; Lee, KL; Marusic, S; McKew, JC; Pelker, JW; Shen, MW; Shimizu, T; Stedman, NL; Thakker, P; Wolf, SF; Xu, X | 1 |
| Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Phillips, JM; Steele, VE | 1 |
2 review(s) available for zileuton and naproxen
| Article | Year |
|---|---|
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
Topics: Animals; Arachidonate 5-Lipoxygenase; Asthma; Eosinophils; Humans; Inflammation; Leukotriene Antagonists; Lipoxygenase Inhibitors; Lung Diseases; Neutrophils; Quinolines | 1992 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for zileuton and naproxen
| Article | Year |
|---|---|
The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Digestive System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Endoscopy; Humans; Hydroxyurea; Intestinal Mucosa; Leukotriene B4; Lipoxygenase Inhibitors; Male; Naproxen; Thromboxane B2 | 1995 |
20 other study(ies) available for zileuton and naproxen
| Article | Year |
|---|---|
Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Female; Male; Quinolines; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Rats, Wistar | 1995 |
1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Arthritis; Bone Density; Cyclooxygenase Inhibitors; Cytokines; Imidazoles; Lipoxygenase Inhibitors; Mice; Mice, Inbred BALB C; Molecular Structure; Morpholines; Prostaglandin-Endoperoxide Synthases; Protein Kinases; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 1996 |
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
Topics: Anaphylaxis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Design; Humans; Hydroxyurea; Ibuprofen; Indomethacin; Leukocytes; Leukotriene E4; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Male; Naproxen; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Tumor Cells, Cultured | 1997 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Benzoates; Biological Availability; Bronchoconstriction; Calorimetry; Carrageenan; Cell Line; Cyclooxygenase 2 Inhibitors; Edema; Group IV Phospholipases A2; Humans; In Vitro Techniques; Isoenzymes; Male; Mice; Protein Binding; Rats; Rats, Sprague-Dawley; Sheep; Structure-Activity Relationship; Sulfonamides | 2008 |
Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.
Topics: Animals; Enzyme Inhibitors; Group IV Phospholipases A2; Hydrophobic and Hydrophilic Interactions; Rats; Structure-Activity Relationship; Sulfides; Sulfonamides | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Base Sequence; Cell Line; Chloramphenicol O-Acetyltransferase; Cyclooxygenase Inhibitors; DNA Primers; Gene Expression; HeLa Cells; Humans; Hydroxyurea; Interleukin-6; Ionomycin; Kinetics; Lipoxygenase Inhibitors; Mice; Molecular Sequence Data; Naproxen; NF-kappa B; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-myc; Pyrazoles; Recombinant Proteins; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured | 1995 |
LTB4-induced transient neutropenia in the rat: a model for evaluating efficacy and bioavailability of LTB4 receptor antagonists.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Dexamethasone; Hydroxyurea; Indomethacin; Leukocyte Count; Leukotriene B4; Male; Models, Biological; Naproxen; Neutropenia; Neutrophils; Rats; Rats, Sprague-Dawley; Receptors, Leukotriene B4 | 1993 |
Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Base Sequence; Binding, Competitive; Cell Movement; E-Selectin; Hydroxyurea; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Lipoxygenase Inhibitors; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Naproxen; Neutrophils; Pyrazoles; Skin; Tumor Necrosis Factor-alpha | 1996 |
The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chronic Disease; Disease Models, Animal; Drug Combinations; Exudates and Transudates; Female; Hydroxyurea; Inflammation; Leukotriene B4; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Naproxen; Prostaglandin-Endoperoxide Synthases; Quinolines; Time Factors; Zymosan | 1996 |
In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
Topics: Adult; Anti-Allergic Agents; Anti-Inflammatory Agents; Anticoagulants; Blood Proteins; Chromatography, High Pressure Liquid; Drug Interactions; Female; Hematocrit; Humans; Hydroxylation; Hydroxyurea; Ibuprofen; In Vitro Techniques; Isotope Labeling; Lipoxygenase Inhibitors; Male; Naproxen; Prednisolone; Protein Binding; Salicylates; Stereoisomerism; Terfenadine; Theophylline; Warfarin | 1995 |
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Topics: Analysis of Variance; Animals; Benzoates; Cell Proliferation; Cells, Cultured; Cyclooxygenase Inhibitors; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Female; Glycoproteins; Group IV Phospholipases A2; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Myelin-Oligodendrocyte Glycoprotein; Naproxen; Peptide Fragments; Severity of Illness Index; Seveso Accidental Release; Sulfonamides; Th1 Cells; Time Factors | 2008 |
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Gene Expression; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mouth Neoplasms; Naproxen; Piroxicam; Pyrazoles; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Up-Regulation | 2010 |